Peloton Wealth Strategists’s 4D Molecular Therapeutics FDMT Stock Holding History

Peloton Wealth Strategists’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$333K	Hold	25,000	–	–	0.12%	82
2026 Q1	$233K	Hold	25,000	–	–	0.09%	84
2025 Q4	$188K	Hold	25,000	–	–	0.07%	90
2025 Q3	$217K	Hold	25,000	–	–	0.09%	89
2025 Q2	$93K	Hold	25,000	–	–	0.04%	89
2025 Q1	$81K	Hold	25,000	–	–	0.03%	92
2024 Q4	$139K	Hold	25,000	–	–	0.06%	92
2024 Q3	$270K	Hold	25,000	–	–	0.11%	89
2024 Q2	$525K	Hold	25,000	–	–	0.22%	76
2024 Q1	$797K	Hold	25,000	–	–	0.32%	68
2023 Q4	$507K	Hold	25,000	–	–	0.22%	76
2023 Q3	$318K	Buy	+25,000	New	+$418K	0.15%	83
2023 Q2	–	Sell	-16,000	Closed	-$275K	–	89
2023 Q1	$275K	Sell	16,000 -21,000	-57%	-$408K	0.13%	81
2022 Q4	$822K	Sell	37,000 -14,000	-27%	-$216K	0.4%	65
2022 Q3	$410K	Buy	51,000 +20,386	+67%	+$185K	0.21%	72
2022 Q2	$214K	Buy	+30,614	New	+$298K	0.1%	85

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Peloton Wealth Strategists's FDMT Position: Q2 2026 in Review

Peloton Wealth Strategists held its 4D Molecular Therapeutics (FDMT) position steady in Q2 2026 at 25,000 shares worth $333K. The position accounts for 0.12% of the portfolio, ranked #82.

Peloton Wealth Strategists first reported a position in FDMT in Q2 2022 and has held it in 16 quarters since. The position peaked at $822K in Q4 2022. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Peloton Wealth Strategists held 25,000 shares of 4D Molecular Therapeutics worth $333K as of Q2 2026.
Peloton Wealth Strategists left its 4D Molecular Therapeutics share count unchanged in Q2 2026.
4D Molecular Therapeutics made up 0.12% of Peloton Wealth Strategists's portfolio in Q2 2026, its #82 holding.
Peloton Wealth Strategists first reported a position in 4D Molecular Therapeutics in Q2 2022 and has held it in 16 quarters since.
Peloton Wealth Strategists's 4D Molecular Therapeutics position peaked at $822K in Q4 2022.
158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Peloton Wealth Strategists's 13F filing for Q2 2026, filed 10 Aug 2026.